Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR1B | P28222 | 2/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HTR1E | P28566 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029939 | 0.92 | DRD2 (0.44) | HTR1AHTR1BHTR1DDRD2RORC | |
| SCHEMBL1178551 | 0.92 | DRD2 (0.44) | HTR1AHTR1BHTR1DDRD2RORC | |
| SCHEMBL1178547 | 0.92 | DRD2 (0.44) | HTR1AHTR1BHTR1DDRD2RORC | |
| SCHEMBL1874947 | 0.91 | HTR1B (0.52) | HTR1AHTR1BHTR1DDRD2DRD4 | |
| SCHEMBL1874943 | 0.91 | HTR1B (0.52) | HTR1AHTR1BHTR1DDRD2DRD4 | |
| SCHEMBL7032822 | 0.87 | HTR1A (0.47) | HTR1AHTR1BHTR1DDRD2DRD4 | |
| SCHEMBL14624292 | 0.85 | HTR1B (0.53) | HTR1AHTR1BHTR1DDRD2DRD4 | |
| SCHEMBL1899835 | 0.85 | HTR1A (0.51) | HTR1AHTR1BHTR1DDRD2DRD4 | |
| SCHEMBL1903598 | 0.85 | HTR1A (0.51) | HTR1AHTR1BHTR1DDRD2DRD4 | |
| SCHEMBL12637107 | 0.85 | HTR1A (0.51) | HTR1AHTR1BHTR1DDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-5827871-A | VASODILATION DISORDERS, ESPECIALLY MIGRAINE HEADACHES; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM PLC (GB) | 1998-10-27 | — | — | US | disclosed |
| EP-0603432-B1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1998-10-21 | — | — | EP | disclosed |
| EP-0591280-B1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5637611-A | Medicaments | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-06-10 | — | — | US | disclosed |
| US-5464864-A | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-11-07 | — | — | US | disclosed |
| EP-0603432-A1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, CYP17A1 | HTR1A 1299/4885HTR1B 1072/4885HTR1D 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.